Showing results (411-420 of 554) with videos related to
Sort By:
Pageof 56
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2015
Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal CancerLiang Zhang, Xiaoen Wang, Andrea J Bullock, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Tissue-based research in kidney cancer: current challenges and future directionsSabina Signoretti, Gennady Bratslavsky, Frederick M Waldman, et al.Journal for Immunotherapy of Cancer|November 20, 2021
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067Meredith M Regan, Charlene M Mantia, Lillian Werner, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2016
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell CarcinomaMartin H Voss, Rupal S Bhatt, Elizabeth R Plimack, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2022
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell CarcinomaThomas Denize, Yue Hou, Jean-Christophe Pignon, et al.Kidney International|May 17, 2013
Divergent functions of the Rho GTPases Rac1 and Cdc42 in podocyte injurySimone M Blattner, Jeffrey B Hodgin, Masashi Nishio, et al.Oncotarget|December 22, 2017
Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expressionAly-Khan A Lalani, Kathryn P Gray, Laurence Albiges, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2010
Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanomaKazuo Koyanagi, Steven J O'Day, Peter Boasberg, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology GroupLawrence E Flaherty, Megan Othus, Michael B Atkins, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trialsEdward L Korn, Ping-Yu Liu, Sandra J Lee, et al.Pageof 56